Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Blueprint Medicines (BPMC) Tops Q4 EPS by 9c
February 17, 2021 7:14 AM ESTBlueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($1.53), $0.09 better than the analyst estimate of ($1.62). Revenue for the quarter came in at $34.1 million versus the consensus estimate of $29.24 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
... More